基因检测在乳腺癌预后研究中的进展
| 作者: |
1孔令红,
2万智毅,
1刘晓刚
1 北京市垂杨柳医院病理科，北京 100022 2 中国农业大学生物学院农业生物技术国家重点实验室，北京 100193 |
| 通讯: |
刘晓刚
Email: chinalark@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2018.02.027 |
| 基金: | 北京市垂杨柳医院硕博基金(2015-02)。 |
摘要
准确预测术后的复发风险，对制定适合乳腺癌患者的治疗方案十分重要。然而传统的临床病理指标并不能准确评估患者个体化的复发风险以筛选出不需要辅助化疗的低复发风险人群。随着基因组学的发展，已有多种基因检测方法被证实可用于乳腺癌预后，评估更个体化更准确的复发风险。这些检测方法包括70基因检测(MammaPrint)、21基因检测(Oncotype DX)、PAM 50、EndoPredict、循环肿瘤DNA(ctDNA)检测等。
关键词：
乳腺癌；预后；21基因；Oncotype DX；70 基因；MammaPrint；ctDNA
Research progress of gene test in breast cancer prognosis
CorrespondingAuthor: LIU Xiaogang Email: chinalark@163.com
DOI: 10.3978/j.issn.2095-6959.2018.02.027
Foundation: This work was supported by Master & Doctor Fund of Beijing Chuiyangliu Hospital, China (2015-02).
Abstract
Accurate prediction of recurrence risk is of vital importance for formulating suitable therapeutic plan for individual breast cancer patients. However, conventional clinicopathological criteria are not accurate enough to select subsets of patients who are at sufficiently low risk of recurrence to be spared adjuvant chemotherapy. With the development of genomics, several gene assays have been confirmed to accurately assess the individual recurrence risk for breast cancer prognosis. These assays include MammaPrint, Oncotype DX, PAM 50, EndoPredict, circulating tumor DNA (ctDNA), etc.
Keywords：
breast cancer; prognosis; 21-gene; Oncotype Dx; 70-gene; MammaPrint; ctDNA